Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: AstraZeneca
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Amiens, France | Recruiting |
| Research Site | Angers, France | Not Yet Recruiting |
| Research Site | Antony, France | Recruiting |
| Research Site | Argenteuil, France | Recruiting |
| Research Site | Avignon, France | Recruiting |
| Research Site | Avignon, France | Not Yet Recruiting |
| Research Site | Besançon, France | Recruiting |
| Research Site | Bordeaux, France | Not Yet Recruiting |
| Research Site | Bordeaux, France | Recruiting |
| Research Site | Bordeaux, France | Withdrawn |
| Research Site | Challes-les-Eaux, France | Recruiting |
| Research Site | Chambray-lès-Tours, France | Recruiting |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06031805